Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study.
In non-diabetics, low levels of soluble receptor for advanced glycations end products (sRAGE) associate with an increased risk of development of diabetes, cardiovascular afflictions, or death. The majority of studies in non-diabetics report an inverse relationship between measures of obesity, cardiometabolic risk factors and sRAGE and/or endogenous secretory RAGE (esRAGE) levels. To elucidate whether this inconsistency is related to the metabolically healthy obese phenotype, or a different impact of the risk factors in presence and absence of obesity, we analyzed data from 2206 apparently healthy adolescents (51 % girls) aged 15-to-19 years. The association of sRAGE levels with soluble vascular adhesion protein-1/semicarbazide sensitive amine oxidase (sVAP-1/SSAO) was also investigated. Centrally obese, including metabolically healthy, adolescents present significantly lower sRAGE and esRAGE, but not sVAP-1, levels in comparison with their lean counterparts. An increasing number of cardiometabolic risk factors did not associate with significant changes in sRAGE, esRAGE or sVAP-1 levels either in lean or in obese subjects. In multivariate analyses, WHtR, hsCRP, markers of glucose homeostasis, renal function, adiponectin, and sVAP-1 associated significantly with sRAGE and esRAGE. SVAP-1 correlated significantly with glycemia, adiponectin, hsCRP, and sRAGE. Thus, in adolescents, a decline in sRAGE and esRAGE precedes the development of metabolic syndrome. When combined, standard and non-standard cardiometabolic risk factors explain only minor proportion in a variability of sRAGE and esRAGE (8 %-11 %); or sVAP-1 (12 %-20 %). Elucidation of pathogenetic mechanisms underlying early decline in sRAGE and esRAGE levels in obese adolescents and their clinical impact with regard to future cardiometabolic health requires further studies.
Faculty of Medicine, Institute of Molecular BioMedicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia.|Faculty of Medicine, Institute of Medical Physics, Biophysics, Informatics and Telemedicine, Comenius University, Bratislava, Slovakia.
Radana
R
Gurecká
Faculty of Medicine, Institute of Molecular BioMedicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia.
Ivana
I
Koborová
Faculty of Medicine, Institute of Molecular BioMedicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia.
Melinda
M
Csongová
Slovak Academy of Sciences, Institute of Materials & Machine Mechanics, Bratislava, Slovakia.
Jozef
J
Šebek
Faculty of Medicine, Institute of Molecular BioMedicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia. kata.sebekova@gmail.com.
Katarína
K
Šebeková
D000293:Adolescent; D006631:Amine Oxidase (Copper-Containing) / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D015815:Cell Adhesion Molecules / Q000097:blood*; D005260:Female; D006331:Heart Diseases / Q000097:blood*; D006801:Humans; D008297:Male; D009765:Obesity / Q000097:blood*; D000067759:Receptor for Advanced Glycation End Products / Q000097:blood*; D012307:Risk Factors
C000593871:AGER protein, human; D015415:Biomarkers; D015815:Cell Adhesion Molecules; D000067759:Receptor for Advanced Glycation End Products; C076668:AOC3 protein, human; D006631:Amine Oxidase (Copper-Containing)
Adolescents; Cardiometabolic risk factors; Microinflammation; Obesity; esRAGE; sRAGE; sVAP-1